Peptide appearance Lyophilized form

Muscle Growth

15 000+ verified orders

Ipamorelin

In stock

Ipamorelin represents a synthetic pentapeptide derived from GHRP-1, which has a very potent growth hormone (GH) releasing properties with efficacy and potency comparable to GHRP-6, both in vitro and in vivo. Unlike other GH secretagogues, ipamorelin very surprisingly does not induce a significant increase in adrenocorticotropic hormone (ACTH) or cortisol levels. This selectivity is crucial, as many other GH secretagogues also stimulate the release of ACTH and cortisol, which can lead to unwanted side effects. It also increases bone mineral content, production of IGF-1 and insulin or muscle growth.
Available strengths
44,50 €
Buy 2, get 1 free. €100 in paid peptide vials · water excluded
Bundle & save

Arrives 26 – 30 November to Europe

We accept Visa Mastercard Apple Pay (when supported) Google Pay (when supported) Klarna (where available) Shown at checkout

Ipamorelin

44,50 €

Selective GHSR peptide for ghrelin receptor and endocrine marker studies.

SKU: ADRIA-IPAMORELIN Categories: ,

Compound information

Specifications

Molecular profile

Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular mass
711.9 g/mol
CAS number
170851-70-4
Molecular formula
C38H49N9O5

Material record

Physical appearance
White to off-white lyophilized powder
Solubility
Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
Product note
Selective growth hormone secretagogue peptide; supplied strictly for research use only.

Research overview

Ipamorelin

Description of Ipamorelin

In terms of efficacy, ipamorelin has similar or higher potency compared to GHRP-6 in various animal models, but it stands out due to its unique lack of effect on other hormones such as prolactin, follicle stimulating hormone (FSH), luteinizing hormone (LH), PRL, and thyroid stimulating hormone (TSH). This makes ipamorelin a promising candidate for further clinical development as it provides targeted GH release without the additional stress response typically associated with other GH secretagogues. Ipamorelin was originally developed by company Novo Nordisk, and was investigated in phase II clinical trials by Helsinn Therapeutics for treatment of postoperative ileus.

[1]

Overview of Published Research

Ipamorelin has shown promising effects in research into counteracting the catabolic impacts of glucocorticoids (GC) on muscle strength and bone formation in adult rats. In a study involving 8-month-old female rats injected with methylprednisolone (GC), the combination treatment with Ipamorelin significantly increased muscle strength and periosteal bone formation. Specifically, the maximum tetanic tension of the calf muscles was higher, and the bone formation rate was four times greater in rats treated with both GC and Ipamorelin compared to those injected with GC alone. This finding suggests that Ipamorelin may mitigate the negative effects of glucocorticoids on muscle and bone, representing an area of research interest in the context of maintaining skeletal muscle function and bone formation during GC treatment.

[2]

In a related study, Ipamorelin and GHRP-6 were evaluated for their effects on bone mineral content (BMC) in young adult female rats. The research indicated that both GHS compounds increased body weight and total tibial and vertebral BMC measured by dual X-ray absorptiometry (DXA). However, total BMC, when adjusted for body weight, remained unchanged. The increased bone formation was attributed to larger bone dimensions and increased cortical cross-sectional area, as determined by in vitro measurements with peripheral quantitative computed tomography (pQCT) and Archimedes' principle. Although cortical volumetric bone mineral density (BMD) and mineral concentration remained unchanged, the findings suggest that GHS treatments can lead to an increase in bone size without necessarily impacting bone density. These studies point to the potential research interest of Ipamorelin and other GHS compounds in the context of bone health and countering muscle and bone degradation.

[3]

Given that glucocorticoids often lead to muscle wasting, the potential of GH and its secretagogues to reduce catabolic effects is an active area of research. The ability of ipamorelin to decrease nitrogen wasting and improve organ nitrogen content in rats treated with prednisolone suggests that it may represent a subject of interest in research into preventing muscle atrophy and other catabolic effects associated with steroid treatment. By influencing muscle loss and nitrogen balance in research models, these substances could provide further avenues for investigating the adverse side effects of glucocorticoid treatment.

Growth hormone (GH) and growth hormone secretagogues like ipamorelin have been shown to mitigate the catabolic effects of glucocorticoids on nitrogen balance and urea synthesis in the liver. In a study involving rats, prednisolone, a glucocorticoid, was found to increase the hepatic capacity for urea-N synthesis (CUNS) and elevate the expression of urea cycle genes, which contributes to nitrogen loss. This treatment also led to a decrease in nitrogen balance and reduced nitrogen content in various organs. However, co-administration of GH reduced CUNS by 33%, normalized urea cycle gene expression, and improved nitrogen balance by 2.5 times. Similarly, ipamorelin decreased CUNS by 20%, reduced the expression of urea cycle enzymes, and improved nitrogen balance, albeit less efficiently than GH.

[4]

Ipamorelin has been shown to stimulate insulin release from the pancreas of both normal and diabetic rats. In a study investigating the mechanism of this effect, researchers used pancreatic tissue fragments from normal and diabetic rats. The results indicated that ipamorelin evoked significant increases in insulin secretion at varying concentrations. This insulin-stimulating effect could be inhibited by different agents such as diltiazem, yohimbine, propranolol, or a combination of atropine, propranolol, and yohimbine. Interestingly, atropine caused a significant reduction in ipamorelin-induced insulin secretion in diabetic but not in normal rats.

These results may be relevant to further research into diabetes. The observed ability of ipamorelin to influence insulin release suggests that this compound could be of research interest in the context of diabetes mellitus, particularly type 2 diabetes, where insulin secretion is impaired. Further research on ipamorelin's interaction with calcium channels and adrenergic receptors in the pancreas could lead to novel research approaches aimed at understanding insulin secretion and glucose regulation in diabetic models. This study lays the groundwork for exploring ipamorelin's potential in this field.

[5]

Postoperative ileus (POI) is a significant complication following certain types of surgery, especially after bowel resection. It is characterized by delayed gastrointestinal motility, leading to increased hospital stay and longer recovery times. This condition is marked by abdominal discomfort, bloating, and an inability to tolerate oral nutrition. Recent studies have explored the potential of ipamorelin, a ghrelin receptor agonist, in accelerating gastrointestinal recovery in subjects with POI.

Proof-of-concept clinical trials have assessed the safety and activity of ipamorelin in the context of POI symptoms. In a randomized controlled study, intravenous administration of ipamorelin was evaluated in patients undergoing abdominal surgery. Results suggested that ipamorelin reduced the time to first tolerated meal by approximately 7 hours, compared to placebo. However, the results were not statistically significant, indicating limited observed activity, and need of more specific research.

[6]

The ghrelin receptor is overexpressed in various conditions like human carcinoma and heart failure, making it a potential target for disease diagnosis and staging. Researchers have been exploring the use of positron emission tomography (PET) imaging to detect ghrelin receptor activity. Recent work has focused on the development of PET probes from peptidic and peptidomimetic derivatives of growth hormone secretagogues (GHSs). This opens up new possibilities for tracking ghrelin receptor activity in different diseases, and ipamorelin is able to bind ghrelin receptors very strongly.

[7]

All presented information is based on scientific publications which can be found in

For laboratory purposes and personal observation only. Not for human consumption.

Laboratory care

Handling

Peptides in transport

Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.

Storage of lyophilized peptides

Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Up to 3 months
  • Refrigerated (2–8 °C): Up to 6 months
  • Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)

Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.

Storage of reconstituted peptides

Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.

The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Avoid prolonged storage
  • Refrigerated (2–8 °C): Typically 4–8 weeks
  • Frozen (-20 °C or below): Up to 3–4 months

To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.

Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.

Analytical documentation

Tests

Latest published result

Liquilabs s.r.o.Signed Certificate of Analysis · 10mg

> 99.8%Purity by HPLC

Batch number
2025290
Tested
2026-05-28

Recorded QC panel

AssayPeptide screening
9.13 mg
PurityPeptide screening
> 99.8%
Identity (FTIR)FTIR spectrum
995
Identity (RT)Retention time
0.983

These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.

See all test results

Signed certificate

Source record

References

1.

K. Raun et al., "Ipamorelin, the first selective growth hormone secretagogue," Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]

2.

N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, "The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats," Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]

3.

J. Svensson et al., "The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats," J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]

4.

N. K. Aagaard et al., "Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats," Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 19, no. 5, pp. 426–431, Oct. 2009. [PubMed]

5.

E. Adeghate and A. S. Ponery, "Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats," Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]

6.

D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients," Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]

7.

M. M. Fowkes, T. Lalonde, L. Yu, S. Dhanvantari, M. S. Kovacs, and L. G. Luyt, "Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor," Eur. J. Med. Chem., vol. 157, pp. 1500–1511, Sep. 2018. [PubMed]

8.

National Center for Biotechnology Information

PubChem Compound Summary: Ipamorelin

Authoritative identity record for Ipamorelin.

PubChem View source ↗
9.

Raun K, Hansen BS, Johansen NL, et al. · 1998

Ipamorelin, the first selective growth hormone secretagogue

Primary receptor-pharmacology study of Ipamorelin.

European Journal of Endocrinology · 10.1530/eje.0.1390552 View source ↗
10.

Venkova K, Mann W, Nelson R, et al. · 2009

Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus

Primary study using Ipamorelin in a defined rodent research model.

Journal of Pharmacology and Experimental Therapeutics · 10.1124/jpet.108.149211 View source ↗
11.

Chemical Abstracts Service

CAS Common Chemistry: 170851-70-4

Authoritative CAS Registry Number record for Ipamorelin.

CAS Common Chemistry View source ↗
12.

Gobburu JV, Agersø H, Jusko WJ, Ynddal L · 1999

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Pharmaceutical research View source ↗
13.

Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H · 1999

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society View source ↗
14.

Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group · 2014

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

International journal of colorectal disease View source ↗
15.

Shrestha P, Sabharwal G, Ghaffari G · 2018

A Novel STAT3 Gene Mutation Related Hyper-IgE Syndrome Misdiagnosed as Hidradenitis Suppurativa

Case reports in immunology View source ↗
16.

N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund · 2001

The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats

Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc
17.

J. Svensson et al. · 2000

The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats

J. Endocrinol
18.

N. K. Aagaard et al. · 2009

Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats

Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc
19.

E. Adeghate and A. S. Ponery · 2004

Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats

Neuro Endocrinol. Lett

Customer reviews

4.7/5185+ reviews
View on Trustpilot ↗Checked 17 Nov 2026

Quality products,fast shipping,great refferal plan,only downside is that products in 4 mounths since my first order got more and more expensive ,but overall verry good experience.

Read full review →

More than 2 weeks for package dispatch. They promised one free peptide next time. Sent me new tracking number but package still wasn't delivered to fedex. Last package (much much cheaper) was delivered in less than week. I will update if they will send my package. ok,package sent.

Read full review →

Extremely satisfied with the product quality and overall experience. The customer service is polite and quick. All recommendations!

Read full review →

Trustworthy site with a huge catalog of products. Been purchasing from them for some time now never got disappointed. I could only recommend them.

Read full review →

Everything ok. With little problem with package, but after contact with Customer Service everything went right. Good quality of products

Read full review →

Excellent. Buying peptides online can be nerve wracking! But Adria are very transparent about all the checks and certifications. My experience with them was excellent. Great products at good prices and efficient P&P

Read full review →